Cure8

Why This Matters

PFAS exposure is widespread; if PFNA worsens intestinal inflammation through a defined immune pathway, it could help explain environmental contributions to IBD flares and point to new research targets for mitigation.

Who Should Pay Attention

Researchers studying IBD pathogenesis or environmental triggers; clinicians interested in environmental health and IBD; patients and advocates concerned about PFAS exposure and gut inflammation.

Study Snapshot

Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract

What To Know

This study (abstract) reports that exposure to a PFAS chemical, perfluorononanoic acid (PFNA), increased intestinal inflammation in mice and in primary mouse macrophages. The authors link the effect to activation of a caspase-11–dependent noncanonical NLRP3 inflammasome pathway, with increased IL‑1β and IL‑18 and markers of pyroptosis (caspase‑1, N‑GSDMD).

The study used molecular docking and genetic or pharmacologic inhibition (caspase‑11 knockdown, Z‑VAD‑FMK) to probe the mechanism, and found that myricetin reduced PFNA‑induced inflammation in their models.

The report is preclinical and based on mouse cells and a chronic colitis mouse model; it does not provide human clinical data or treatment recommendations. The findings suggest a specific immune pathway by which PFNA can worsen intestinal inflammation and point to myricetin as an experimental modifier in these models.

If you follow environmental health concerns, this adds to evidence that certain PFAS chemicals can affect gut inflammation, but translation to human IBD risk or therapy is not established.

Keep In Mind

This is a basic-science, preclinical study using mouse cells and a mouse colitis model (abstract-level summary). It does not demonstrate effects in people or support clinical use of myricetin. Environmental PFAS exposure levels and relevance to human IBD require further epidemiologic and clinical research.

Source Details

Review the original publication for the complete reporting, methods, and context.

Read Original Source
Research paper Evidence type derived from source or registry metadata.
PublicationJournal of advanced research
AuthorsKean Lu, Zhenyan Cui, Xiaohong Fei +6 more
InstitutionDepartment of Toxicology of School of Public Health and Department of Gynecologic Oncology of Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedSep 4, 2026, 12:00 AM
Content availableJournal abstract

Conflict statement: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.

Related Reading

Browse latest news →